Search results
Showing 736 to 750 of 1330 results for nice quality standards or clinical guidelines
Apremilast for treating moderate to severe plaque psoriasis (TA419)
Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults.
LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis (MIB317)
NICE has developed a medtech innovation briefing (MIB) on LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis .
Molecular testing strategies for Lynch syndrome in people with colorectal cancer (HTG430)
Evidence-based recommendations on using immunohistochemistry or microsatellite instability testing to guide further testing for Lynch syndrome in people with colorectal cancer.
FebriDx for C-reactive protein and myxovirus resistance protein A testing (MIB224)
NICE has developed a medtech innovation briefing (MIB) on FebriDx for C-reactive protein and myxovirus resistance protein A testing .
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)
Evidence-based recommendations on canagliflozin (Invokana), dapagliflozin (Forxiga) and empagliflozin (Jardiance) as options for treating type 2 diabetes in adults.
Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making
Late-stage assessment (LSA) guidance on intermittent urethral catheters for chronic incomplete bladder emptying in adults.
Digital technologies to support self-management of COPD: early value assessment (HTG736)
Early value assessment (EVA) guidance on digital technologies to support self-management of COPD.
NICE has developed a medtech innovation briefing (MIB) on Fungitell for antifungal treatment stratification .
MMprofiler for prognostic risk classification in multiple myeloma (MIB270)
NICE has developed a medtech innovation briefing (MIB) on MMprofiler for prognostic risk classification in multiple myeloma .
Evidence-based recommendations on quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care.
Mirabegron for treating symptoms of overactive bladder (TA290)
Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.
Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (HTG320)
Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative colitis) and non-inflammatory bowel diseases (such as irritable bowel syndrome).
Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)
Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy.
Evidence-based recommendations on aripiprazole for treating moderate to severe manic episodes in young people with bipolar I disorder.